轻度认知障碍中PET淀粉样配体[11C]PIB摄取与脑脊液β淀粉样蛋白的关系

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.

作者信息

Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka S-K, Jauhianen A M, Hänninen T, Hallikainen M, Någren K, Rinne J O, Soininen H

机构信息

Turku PET Centre, University of Turku, Turku, Finland.

出版信息

Dement Geriatr Cogn Disord. 2008;26(4):378-83. doi: 10.1159/000163927. Epub 2008 Oct 16.

DOI:10.1159/000163927

PMID:18931497

Abstract

BACKGROUND

In mild cognitive impairment (MCI), Alzheimer's disease (AD)-type cerebrospinal fluid (CSF) biomarker profiles predict rapid progression and conversion to AD. An increased brain amyloid burden in AD and MCI has been demonstrated with PET using [(11)C]PIB (Pittsburgh compound B). Little is known about the relationship between these biomarkers in MCI.

METHODS

We studied 15 patients with amnestic MCI and 22 controls with PET using [(11)C]PIB. In MCI patients, CSF levels of Abeta42, pTAU, totalTAU and the Abeta42/pTAU ratio were measured.

RESULTS

In MCI patients, CSF Abeta42 was abnormal in 53% of patients, totalTAU in 67%, pTAU in 64% and the Abeta42/pTAU ratio in 64%. A composite neocortical [(11)C]PIB uptake score was increased in 87% of the MCI patients. Only 54% of [(11)C]PIB-positive subjects showed AD-type Abeta42 values. During a 2-year follow-up, 6 MCI patients converted to AD, all of them had increased neocortical PIB scores at the MCI stage. Abnormal CSF Abeta42 was found in 3 patients, pTAU in 3 patients and Abeta42/pTAU ratio in 4 patients.

CONCLUSION

Follow-up studies are needed to confirm whether [(11)C]PIB uptake might be more sensitive than CSF Abeta42 concentration in detecting increased amyloid burden in MCI, as suggested by the results of this study.

摘要

背景

在轻度认知障碍（MCI）中，阿尔茨海默病（AD）型脑脊液（CSF）生物标志物谱可预测疾病的快速进展及向AD的转化。使用[（11）C]PIB（匹兹堡化合物B）的PET已证实AD和MCI患者脑内淀粉样蛋白负荷增加。关于MCI中这些生物标志物之间的关系，目前所知甚少。

方法

我们对15例遗忘型MCI患者和22例对照者进行了使用[（11）C]PIB的PET研究。对MCI患者测定了脑脊液中β淀粉样蛋白42（Abeta42）、磷酸化tau蛋白（pTAU）、总tau蛋白（totalTAU）以及Abeta42/pTAU比值。

结果

在MCI患者中，53%的患者脑脊液Abeta42异常，67%的患者totalTAU异常，64%的患者pTAU异常，64%的患者Abeta42/pTAU比值异常。87%的MCI患者复合新皮质[（11）C]PIB摄取评分升高。仅54%的[（11）C]PIB阳性受试者显示出AD型Abeta42值。在为期2年的随访中，6例MCI患者转化为AD，他们在MCI阶段时新皮质PIB评分均升高。3例患者脑脊液Abeta42异常，3例患者pTAU异常，4例患者Abeta42/pTAU比值异常。